Products for Research Use Only

ZJK-807

CAT: 0804-HY-178497Size: 1 EachDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-178497Size:1 Each
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
ZJK-807 is a highly effective and selective PROTAC degrader targeting KRASG12D (DC50 = 79.5 nM in AsPC-1 cells). ZJK-807 shows minimal impact on wild-type KRAS or other mutants (G12C/S/V, G13D), inducing mutant-specific cytotoxicity. ZJK-807 suppresses RAS/MAPK signaling and uniquely modulates TNF signaling and eukaryotic ribosome biogenesis. ZJK-807 can be used for the study of KRAS-driven pancreatic cancer. Yellow: KRASG12D ligand ; Green: E3 ligase CRBN ligand (HY-178507) ; Black: Linker (HY-178506).
UNSPSC
12352005
Target
P38 MAPK; PROTACs; Ras; TNF Receptor
Related Pathways
Apoptosis; GPCR/G Protein; MAPK/ERK Pathway; PROTAC
Applications
COVID-19-immunoregulation
Field of Research
Cancer; Inflammation/Immunology
Smiles
O=C1N(C(CC2)C(NC2=O)=O)C(C3=C1C=CC(N4CC5(CCC(N(C6CN(C7=NC(N8C[C@@](N9)([H])CC[C@@]9([H])C8)=C(C=NC(C%10=C%11C(C#C)=C(F)C=CC%11=CC(O)=C%10)=C%12F)C%12=N7)C6)C)CC5)C4)=C3)=O
Molecular Formula
C50H48F2N10O5
Molecular Weight
906.98
References & Citations
[1]Liu Z, et al. ZJK-807: A Selective PROTAC Degrader of KRASG12D Overcoming Resistance in Pancreatic Cancer. J Med Chem. 2025 Oct 9;68 (19) :20103-20129.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported